Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EARLY: Prospective, Randomised, National, Multi-Centre, Open-Label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-Day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study.

Next Previous
Search
Trial Profile

EARLY: Prospective, Randomised, National, Multi-Centre, Open-Label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-Day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin/dipyridamole (Primary) ; Aspirin
  • Indications Embolism and thrombosis; Stroke; Transient ischaemic attacks
  • Focus Therapeutic Use
  • Acronyms EARLY
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 12 Mar 2010 Actual number of patients changed from 548 to 551 as reported by ClinicalTrials.gov.
  • 01 Feb 2010 Results were published in the Lancet Neurology 9: 159-66, No.2.
  • 16 Sep 2009 Primary endpoint 'Rankin scale' has not been met.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top